295 related articles for article (PubMed ID: 15018851)
1. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Ducancelle A; Belloc S; Alain S; Scieux C; Malphettes M; Petit F; Brouet JC; Sanson Le Pors MJ; Mazeron MC
J Clin Virol; 2004 Apr; 29(4):241-7. PubMed ID: 15018851
[TBL] [Abstract][Full Text] [Related]
2. Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Pérez JL
Microbiologia; 1997 Sep; 13(3):343-52. PubMed ID: 9353754
[TBL] [Abstract][Full Text] [Related]
3. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
4. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
5. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Chou S; Miner RC; Drew WL
J Infect Dis; 2000 Dec; 182(6):1765-8. PubMed ID: 11069251
[TBL] [Abstract][Full Text] [Related]
6. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
7. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Chou S; Marousek G; Guentzel S; Follansbee SE; Poscher ME; Lalezari JP; Miner RC; Drew WL
J Infect Dis; 1997 Sep; 176(3):786-9. PubMed ID: 9291334
[TBL] [Abstract][Full Text] [Related]
8. Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Ketteler M; Preuschof L; Mertz A; Stöffler-Meilicke M; Schäfer H; Distler A; Offermann G
Clin Nephrol; 2000 Nov; 54(5):418-24. PubMed ID: 11105806
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus drug resistance.
Emery VC
Antivir Ther; 1998; 3(4):239-42. PubMed ID: 10682146
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
11. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
Bowen EF; Cherrington JM; Lamy PD; Griffiths PD; Johnson MA; Emery VC
J Med Virol; 1999 Aug; 58(4):402-7. PubMed ID: 10421408
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir.
Harada K; Eizuru Y; Isashiki Y; Ihara S; Minamishima Y
Arch Virol; 1997; 142(2):215-25. PubMed ID: 9125039
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus drug resistance and clinical implications.
Chou SW
Transpl Infect Dis; 2001; 3 Suppl 2():20-4. PubMed ID: 11926745
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
Seo SK; Regan A; Cihlar T; Lin DC; Boulad F; George D; Prasad VK; Kiehn TE; Polsky B
Clin Infect Dis; 2001 Nov; 33(9):e105-8. PubMed ID: 11577375
[TBL] [Abstract][Full Text] [Related]
15. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
16. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
[TBL] [Abstract][Full Text] [Related]
17. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
18. Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Chakrabarti S; Collingham KE; Osman H; Fegan CD; Milligan DW
Bone Marrow Transplant; 2001 Nov; 28(9):879-81. PubMed ID: 11781649
[TBL] [Abstract][Full Text] [Related]
19. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
Erice A; Gil-Roda C; Pérez JL; Balfour HH; Sannerud KJ; Hanson MN; Boivin G; Chou S
J Infect Dis; 1997 May; 175(5):1087-92. PubMed ID: 9129070
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
